Aims-To investigate the kinetics of normalisation of monocyte oxidative activity following tumour eradication. Methods-Whole blood lucigenin enhanced chemiluminescence was studied in patients with non-seminomatous germ cell tumours. Group 1 comprised 14 patients who had been "cured" of their cancer (the term "cured" as used in this report denotes a relapse free period of at least three years). Group 2 comprised 15 patients who were followed from diagnosis to up to two years after the start of treatment. Results-Lucigenin enhanced chemiluminescence of whole blood in the "cured" patients was similar to that of controls and lower than that in patients who had not yet received chemotherapy (group 2 (TNFct), a cytotoxic molecule secreted by activated monocytes, in addition to its cytotoxic activity,'3 4 also has broad immunomodulating effects.'5-18 Earlier studies have shown that the chemiluminescence activity of whole blood is increased in patients with cancer," 12 suggesting that monocyte activity is increased in these patients. The increased activity, however, did not seem to be related to cancer spread. In fact, there was a tendency towards lower monocyte activity in patients with metastases. The cause of this increased monocyte activity in patients with cancer is not clear and could either be the result of a genetically determined increase in activity in these patients, or a consequence of monocyte activation by products generated by the tumour itself or the principle cells involved in the host response.'9 In an attempt to examine this further we studied whole blood chemiluminescence in patients with non-seminomatous germ cell tumours of the testis. The patient cohort was divided into two groups: those with no signs of relapse at least three years after treatment finished (group 1) and those who were followed from diagnosis to up to two years after treatment started. TNFoc was measured as another marker of monocyte activity"" and ot-fetoprotein (AFP) as a marker of cancer cell growth.2'`23 Methods All patients underwent orchiectomy and the diagnosis of non-seminomatous germ cell tumour of the testis was confirmed by histopathology. After surgery, all of the patients underwent chest x ray and a computed tomography (CT) scan of the pelvis and abdomen. The serum concentrations ofAFP and J human chorionic gonadotropin (P-HCG) were measured before surgery and at each follow up visit. Serum concentrations ofAFP and 3-HCG were regarded as raised if they were above 15 ,ug/l and 5 U/l, respectively. Tumour markers were assessed before the beginning of each chemotherapy cycle and every four to eight weeks on follow up. Radiological examinations were carried out at two to four month intervals.
Defence against cancer spread depends on a variety of reactions, including that of phagocytic cells."A The mechanisms by which these cells eradicate cancer cells are probably analogous to the way microbes are killed-the generation of cytotoxic free radicals derived from oxygen,56 and the production and release of cytotoxic molecules. '7 In whole blood the production of these oxygen radicals by monocytes can be measured by lucigenin enhanced chemiluminescence8-0; previous studies indicated that lucigenin enhanced chemiluminescence reflects the activity of blood monocytes. 12 Tumour necrosis factor a (TNFct), a cytotoxic molecule secreted by activated monocytes, in addition to its cytotoxic activity,'3 4 also has broad immunomodulating effects. '5-18 Earlier studies have shown that the chemiluminescence activity of whole blood is increased in patients with cancer," 12 suggesting that monocyte activity is increased in these patients. The increased activity, however, did not seem to be related to cancer spread. In fact, there was a tendency towards lower monocyte activity in patients with metastases. The cause of this increased monocyte activity in patients with cancer is not clear and could either be the result of a genetically determined increase in activity in these patients, or a consequence of monocyte activation by products generated by the tumour itself or the principle cells involved in the host response. '9 In an attempt to examine this further we studied whole blood chemiluminescence in patients with non-seminomatous germ cell tumours of the testis. The patient cohort was divided into two groups: those with no signs of relapse at least three years after treatment finished (group 1) and those who were followed from diagnosis to up to two years after treatment started. TNFoc was measured as another marker of monocyte activity"" and ot-fetoprotein (AFP) as a marker of cancer cell growth.2'`23 Methods All patients underwent orchiectomy and the diagnosis of non-seminomatous germ cell tumour of the testis was confirmed by histopathology. After surgery, all of the patients underwent chest x ray and a computed tomography (CT) scan of the pelvis and abdomen. The serum concentrations ofAFP and J human chorionic gonadotropin (P-HCG) were measured before surgery and at each follow up visit. Serum concentrations ofAFP and 3-HCG were regarded as raised if they were above 15 ,ug/l and 5 U/l, respectively. Tumour markers were assessed before the beginning of each chemotherapy cycle and every four to eight weeks on follow up. Radiological examinations were carried out at two to four month intervals.
In patients who underwent chemotherapy a complete response was defined as the resolution of all metastatic lesions and normalisation of tumour markers. The definition "cured" as used in this report refers to a relapse free period of at least three years. Relapse/progressive disease was defined as the appearance of new metastatic lesions and/or an increase in AFP and/or P-HCG concentrations. Months after start of treatment Figure 2 Kinetics of lucigenin enhanced chemiluminescence of whole blood. As indicated in the figure, chemiluminescence production decreased 13 
Discussion
The results presented here confirm previous observations of increased lucigenin enhanced chemiluminescence in whole blood of patients with cancer." 12 The data clearly indicate that this production is related to the cancer per se, as in the group ofpatients who were successfully "cured" of their cancer the activity was significantly lower and similar to the production of healthy subjects. Moreover, production was also normalised in the patients followed during and after treatment. Two cell types contribute to lucigenin enhanced chemiluminescence in whole blood, PMN t Significantly decreased in patients before treatment (p<0 01) compared with controls.
The Mann-Whitney U-test was used to compare differences between groups. Values are given as median (range).
of TNFct, may be a further sign of monocyte activation. Increased monocyte activity in cancer could reflect a genetically determined increase in the activity of the monocyte population and render this group ofpatients more prone to developing cancer. This is because oxygen free radicals are potentially mutagenic and carcinogenic.'2 However, a more likely explanation is that the increased activity of the monocytes is a consequence of cancer cell growth and is part of the defence against cancer. Two findings in our present report strongly support the latter interpretation. One is the normal production of chemiluminescence in "cured" patients and the other is the normalisation of the chemiluminescence production in successfully treated patients. Moreover, in previous studies we observed that the increased activity was independent of cancer spread." Indeed, increased monocyte activity in patients with cancer resulting in greater cytostatic and cytotoxic activity against established cultured tumour cells25"2-and increased production of TNFo729 has been reported previously. Raised serum concentrations of TNFcz in patients with solid tumours have also been reported. 2030 An intriguing finding in this study was the long delay in the normalisation of the signs of monocyte activity after eradication of the tumour. Over a year elapsed before whole blood chemiluminescence returned to normal and a little under a year for TNFcx. This means that in spite of successful tumour eradication and although these two variables were raised as a consequence of the presence of the tumour, the monocytes remained activated. This residual activation is probably a result of the immune memory mechanism, in which the interactions between cytokines released by the tumour cells, T lymphocyte activated macrophages, eosinophils, and neutrophils are thought to form an important effector mechanism.3' Although, in the present study, normalisation of chemiluminescence did not reach significance until 13 to 18 months after tumour eradication, in some patients values had returned to normal within a few months, whereas in others chemiluminescence production remained high for up to two years. To what extent the latter may be beneficial to the patient in protecting him/ her against re-establishment of the cancer is uncertain. One could argue that the reason for the continuous activation of the monocytes was the fact that some cancer cells had survived although there was no clinical evidence of this. However, the fact that the two tumour markers, AFP and P-HCG, were quickly normalised after orchiectomy suggests that this is not the case.
To our knowledge this is the first study showing continuous activation of the cellular mechanisms involved in the defence against cancer after eradication of the target cells. Braun et al32 found that monocyte activity normalised shortly after tumour eradication. In the present study, unlike that of Braun et al, manipulation of the cells was kept to a minimum prior to the measurement of their activity, which may have contributed to the different results obtained. We believe that the findings not only of increased production of chemiluminescence, but also of raised serum TNFct concentrations long after tumour eradication strongly support our observations, although the latter may be produced by many other cells. If our findings are confirmed in future studies they could be of great importance in unravelling the mechanisms involved in cancer defence reactions.
How T helper cells and natural killer cells, among others. The continued production of these cytokines after tumour eradication might be responsible for the extended activation of monocytes, as observed in the present study.
In conclusion, whole blood lucigenin enhanced chemiluminescence and TNFot serum concentrations are raised in patients with cancer. Normalisation of these variables occurs slowly with a delay of up to a year after eradication of the tumour. We hypothesise that this reflects the continued activation of the blood monocytes and that this activation is a consequence of the continuous production of vari- 
